Your browser doesn't support javascript.
loading
2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023.
Perkins, Rebecca B; Guido, Richard S; Castle, Philip E; Chelmow, David; Einstein, Mark H; Garcia, Francisco; Huh, Warner K; Kim, Jane J; Moscicki, Anna-Barbara; Nayar, Ritu; Saraiya, Mona; Sawaya, George F; Wentzensen, Nicolas; Schiffman, Mark.
Afiliación
  • Perkins RB; Boston University School of Medicine/Boston Medical Center, Boston, MA.
  • Guido RS; University of Pittsburgh/Magee-Women's Hospital, Pittsburgh, PA.
  • Castle PE; National Cancer Institute, Bethesda, MD.
  • Chelmow D; Virginia Commonwealth University School of Medicine, Richmond, VA.
  • Einstein MH; Rutgers, New Jersey Medical School, Newark, NJ.
  • Garcia F; Pima County Health & Community Services, Tucson, AZ.
  • Huh WK; UAB School of Medicine, Birmingham, AL.
  • Kim JJ; Harvard T.H. Chan School of Public Health, Boston, MA.
  • Moscicki AB; University of California, Los Angeles, Los Angeles, CA.
  • Nayar R; Northwestern University, Feinberg School of Medicine-Northwestern Memorial Hospital, Chicago, IL.
  • Saraiya M; Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA.
  • Sawaya GF; University of California, San Francisco; San Francisco, CA; Division of Cancer Epidemiology and Genetics; and Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.
  • Wentzensen N; National Cancer Institute, Bethesda, MD.
  • Schiffman M; National Cancer Institute, Bethesda, MD.
J Low Genit Tract Dis ; 28(1): 3-6, 2024 Jan 01.
Article en En | MEDLINE | ID: mdl-38117563
ABSTRACT
ABSTRACT This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Displasia del Cuello del Útero / Neoplasias del Cuello Uterino / Infecciones por Papillomavirus Límite: Female / Humans / Pregnancy Idioma: En Revista: J Low Genit Tract Dis Asunto de la revista: GINECOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Displasia del Cuello del Útero / Neoplasias del Cuello Uterino / Infecciones por Papillomavirus Límite: Female / Humans / Pregnancy Idioma: En Revista: J Low Genit Tract Dis Asunto de la revista: GINECOLOGIA Año: 2024 Tipo del documento: Article